
INOVIO Reports Progress on INO-3107 and DNA Medicine, 2024 Financial Outcomes
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) released its financial results and operational highlights for 2024, marking significant strides in its pipeline and the broader development of DNA medicines.
INOVIO Reports Progress on INO-3107 and DNA Medicine, 2024 Financial Outcomes Read More